ALB and neoplasm: In the past decades, albumin emerged as an efficient drug carrier for the enhanced tumor targeting of metal-based drugs either via covalent attachment by using maleimide functional groups47,48 or by non-covalent interactions.49 Our group recently reported several maleimide-functionalized oxaliplatin(iv) prodrugs with distinctly improved anticancer activity over oxaliplatin.12,14 The tumor-specific release of platinum(ii) and potentially synergistic, bioactive axial ligands may also mitigate systemic adverse effects of both released compounds and their combination.